Patents by Inventor Bryan John Smith

Bryan John Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11384148
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 12, 2022
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 11352414
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 7, 2022
    Inventors: Farnaz Fallah-Arani, Robert Anthony Griffin, David Paul Humphreys, Shirley Jane Peters, Bryan John Smith, Paul Edward Stephens
  • Publication number: 20220162311
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: December 9, 2021
    Publication date: May 26, 2022
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Patent number: 11220547
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: January 11, 2022
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • Publication number: 20190270811
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 5, 2019
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Publication number: 20190248890
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Applicant: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 10273302
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • Patent number: 10233243
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 19, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Publication number: 20180127498
    Abstract: The disclosure relates to antibody fusion proteins specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 10, 2018
    Applicant: UCB Biopharma SPRL
    Inventors: Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Paul HUMPHREYS, Bryan John SMITH
  • Patent number: 9957320
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Publication number: 20170088603
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 30, 2017
    Inventors: Farnaz FALLAH-ARANI, Robert Anthony GRIFFIN, David Paul HUMPHREYS, Shirley Jane PETERS, Bryan John SMITH, Paul Edward STEPHENS
  • Publication number: 20170081406
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 23, 2017
    Inventors: Farnaz FALLAH-ARANI, Robert Anthony GRIFFIN, David Paul HUMPHREYS, Shirley Jane PETERS, Bryan John SMITH, Paul Edward STEPHENS
  • Publication number: 20160289323
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: June 13, 2016
    Publication date: October 6, 2016
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Publication number: 20160264668
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: November 12, 2014
    Publication date: September 15, 2016
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Patent number: 9394361
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 19, 2016
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Patent number: 9096887
    Abstract: A method of measuring acidic species generated by degradation of a Fab or Fab? component of a Fab-PEG or a Fab?-PEG is provided. The method involves: a) cleaving PEG and a linker from the Fab-PEG or Fab?-PEG with an enzyme; b) optionally separating the PEG and linker from the Fab or Fab? to provide isolated Fab or Fab?; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab? and/or the cleaved PEG.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: August 4, 2015
    Assignee: UCB PHARMA, S.A.
    Inventors: Bryan John Smith, Helen Marie Kirke
  • Publication number: 20150118240
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 30, 2015
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Publication number: 20140242625
    Abstract: A method of measuring acidic species generated by degradation of a Fab or Fab? component of a Fab-PEG or a Fab?-PEG is provided. The method involves: a) cleaving PEG and a linker from the Fab-PEG or Fab?-PEG with an enzyme; b) optionally separating the PEG and linker from the Fab or Fab? to provide isolated Fab or Fab?; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab? and/or the cleaved PEG.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: UCB PHARMA, S.A.
    Inventors: BRYAN JOHN SMITH, HELEN MARIE KIRKE
  • Publication number: 20140178387
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 26, 2014
    Applicant: UCB Pharma S.A.
    Inventors: NEIL GOZZARD, ALASTAIR DAVID GRIFFITHS LAWSON, DANIEL JOHN LIGHTWOOD, ROGER THOMAS PALFRAMAN, BRYAN JOHN SMITH, KERRY LOUISE TYSON
  • Patent number: 8722353
    Abstract: A method of measuring acidic species generated by degradation of a Fab or Fab? component of a Fab-PEG or a Fab?-PEG is provided. The method involves: a) cleaving PEG and a linker from the Fab-PEG or Fab?-PEG with an enzyme; b) optionally separating the PEG and linker from the Fab or Fab? to provide isolated Fab or Fab?; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab? and/or the cleaved PEG.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: May 13, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Bryan John Smith, Helen Marie Kirke